

July 26, 2023

<p>To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b></p> <p><b>Company Code No. AUOPHARMA</b></p>	<p>To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25<sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b></p> <p><b>Company Code No. 524804</b></p>
---	---

Dear Sir/ Madam,

**Sub: Revised Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Related Party Transactions for the half year ended March 31, 2023**

Further to our letter dated May 27, 2023, and pursuant to Regulation 23(9) of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021, we are enclosing herewith the revised disclosure of Related Party Transactions on a consolidated basis for the half year ended March 31, 2023. Following are the changes made in the related party transactions for the half year ended March 31, 2023, disclosed to the stock exchanges on May 27, 2023.

S. No.	Name of the party	Name of the counter party	Type of transaction	Value of transaction disclosed on May 27, 2023 (INR in Million)	Revised value of transaction (INR in Million)
1	All Pharma (Shanghai) Trading Co. Ltd.	Gelcaps Industries	Sale of Finished goods	0.04	0.27
2	Eugia SEZ Private Limited	Lakshmana Chary Akarapu	Managerial Remuneration	Not disclosed	2.42
3	Eugia Pharma Specialities Ltd.	Venkat Reddy Kupireddy	Managerial Remuneration	Not disclosed	3.67
4	Aurobindo Pharma USA Inc	Axis Clinicals LLC USA	Clinical Services	29.94	0.47
5	Aurobindo Pharma USA Inc	Axis Clinicals Ltd	Bioequivalence	4.82	34.30
6	Aurobindo Pharma Limited	Transaction Square LLP, India	Purchase of goods or services	0.72	2.42
7	Aurobindo Pharma Limited	Crest Cellulose Private limited, India	Purchase of goods or services	121.53	6.00
<b>Total</b>				<b>157.05</b>	<b>49.55</b>

The above corrections under Serial numbers 4&5 and 7 are mainly due to the following reasons and the rest of them are due to reconciliation errors:

**AUROBINDO PHARMA LIMITED**

(CIN : L24239TG1986PLC015190)

[www.aurobindo.com](http://www.aurobindo.com)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 4023736370/23747340 Fax: +91 4023741080/23746833

Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)

The value of services availed by Aurobindo Pharma USA Inc, a wholly owned subsidiary of the Company, from Axis Clinicals Limited was wrongly mentioned against Axis Clinicals LLC USA, a subsidiary of Axis Clinicals Limited, hence corrections under Point numbers 4 & 5.

Whereas, Crest Cellulose Private Limited ceased to be a Related Party to the Company w.e.f. July 4, 2022, but by oversight the value of transactions entered into between the Company and Crest Cellulose Private Limited even after July 4, 2022, was considered in the related party transaction disclosures for the half year ended March 31, 2023 submitted on May 27, 2023, under point number 7.

The revised disclosure is also being uploaded on the website of the Company i.e., [www.aurobindo.com](http://www.aurobindo.com)

Please take the above information on record.

Thanking you,

Yours faithfully,  
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy  
Company Secretary



















